Cytokine Release Syndrome and Immune-Related Pneumonitis Associated With Tumor Progression in a Pulmonary Pleomorphic Carcinoma Treated With Nivolumab Plus Ipilimumab Treatment: A Case Report.
JTO Clin Res Rep
; 3(2): 100272, 2022 Feb.
Article
in En
| MEDLINE
| ID: mdl-35072122
Effective control of severe immune-related adverse events, including cytokine release syndrome (CRS), is essential for the success of immunotherapy. We present a case of a granulocyte colony-stimulating factor-producing pleomorphic lung carcinoma treated with nivolumab plus ipilimumab which developed CRS and severe immune-related pneumonitis. The effect of immunotherapy was heterogeneous; gastric metastasis was eliminated, but the pulmonary lesion had primary resistance. Steroid and tocilizumab were successful in controlling CRS, but additional infliximab was necessary to control pneumonitis. To control immune-related adverse events, it is important to choose immunosuppressive agents to the specific target organ and inflammatory cells.
Full text:
1
Collection:
01-internacional
Health context:
4_TD
Database:
MEDLINE
Type of study:
Risk_factors_studies
Language:
En
Journal:
JTO Clin Res Rep
Year:
2022
Document type:
Article